Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a digital tool help sarcoma patients handle treatment side effects?

NCT ID NCT06211257

Symptom relief Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a digital personalized care plan (ePCP) can help people with advanced sarcoma who are on chemotherapy. About 377 participants will either get the digital plan plus standard care, or standard care alone. The main goal is to see if the digital tool reduces severe side effects in the first three months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital personalized care plan (ePCP)
What this could lead to
If it works, this could improve how patients manage severe side effects from sarcoma treatment, making their experience less difficult.
What could go wrong
This is a non-drug intervention, so the benefit may be small or hard to measure. The trial is still recruiting and results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 377 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sarcomas of soft tissues or viscera ; * Inoperable metastatic or locally advanced disease ; * Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ; * Patient covered by French social security ; * Written, signed, informed consent ; Exclusion Criteria: * Prior inclusion in ePPS trial for a prior systemic treatment ; * Poor understanding of French ; * Difficulty accessing a computer ; * Pregnant or nursing woman ; * Person deprived of liberty or under guardianship ; * Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced soft tissue sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroaxonal dystrophy sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced soft tissue sarcoma Sarcoma metastatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Jean Minjoz

    RECRUITING

    Besançon, Bourgogne-Franche-Comté, 25000, France

  • CHU de Poitiers

    RECRUITING

    Poitiers, New Aquitaine, 86021, France

  • Centre Eugène Marquis

    NOT_YET_RECRUITING

    Rennes, Brittany Region, 35042, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, Auvergne-Rhône-Alpes, 69373, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, Hauts-de-France, 59020, France

  • Centre Paul Strauss

    RECRUITING

    Strasbourg, Grand Est, 67033, France

  • Gustave Roussy

    RECRUITING

    Villejuif, Île-de-France Region, 94800, France

  • Hôpital Pitié-Salpêtrière AP-HP

    NOT_YET_RECRUITING

    Paris, Île-de-France Region, 75013, France

  • Institut Claudius Regaud

    WITHDRAWN

    Toulouse, Occitanie, 31059, France

  • Institut de Cancérologie de Lorraine

    NOT_YET_RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Saint-Herblain, Pays de la Loire Region, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.